ALK and non-small cell lung carcinoma: Likewise, with regard to the research on ICIs mentioned previously, studies performed in NSCLC patients treated with ALK tyrosine kinase inhibitors (ALK-TKIs) and EGFR tyrosine kinase inhibitors (EGFR-TKIs) indicated the potential application of ctDNA and VAF analysis in therapy effectiveness prediction.